MA29140B1 - Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10 - Google Patents

Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10

Info

Publication number
MA29140B1
MA29140B1 MA30049A MA30049A MA29140B1 MA 29140 B1 MA29140 B1 MA 29140B1 MA 30049 A MA30049 A MA 30049A MA 30049 A MA30049 A MA 30049A MA 29140 B1 MA29140 B1 MA 29140B1
Authority
MA
Morocco
Prior art keywords
compounds
pde10 inhibitors
quinoline derivatives
relates
heteroaromatic quinoline
Prior art date
Application number
MA30049A
Other languages
English (en)
French (fr)
Inventor
Patrick Robert Verhoest
Christopher John Helal
Dennis Jay Hoover
John Michael Humphrey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA29140B1 publication Critical patent/MA29140B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA30049A 2005-01-07 2007-07-06 Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10 MA29140B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64205805P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
MA29140B1 true MA29140B1 (fr) 2008-01-02

Family

ID=36589327

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30049A MA29140B1 (fr) 2005-01-07 2007-07-06 Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10

Country Status (44)

Country Link
US (2) US7429665B2 (nl)
EP (1) EP1841757B1 (nl)
JP (1) JP4302762B2 (nl)
KR (1) KR100896380B1 (nl)
CN (2) CN101098866A (nl)
AP (1) AP2362A (nl)
AR (1) AR052863A1 (nl)
AT (1) ATE472543T1 (nl)
AU (1) AU2005323794B2 (nl)
BR (1) BRPI0518508A2 (nl)
CA (1) CA2592986C (nl)
CR (1) CR9180A (nl)
CU (1) CU23780B7 (nl)
CY (1) CY1110746T1 (nl)
DE (1) DE602005022115D1 (nl)
DK (1) DK1841757T3 (nl)
EA (1) EA012211B1 (nl)
EG (1) EG25993A (nl)
ES (1) ES2346674T3 (nl)
GE (1) GEP20094623B (nl)
GT (1) GT200600002A (nl)
HK (1) HK1167263A1 (nl)
HN (1) HN2006000668A (nl)
HR (1) HRP20100461T1 (nl)
IL (1) IL183851A (nl)
MA (1) MA29140B1 (nl)
ME (1) ME01142B (nl)
MX (1) MX2007008287A (nl)
MY (1) MY142052A (nl)
NL (1) NL1030863C2 (nl)
NO (1) NO340476B1 (nl)
NZ (1) NZ555737A (nl)
PE (1) PE20060873A1 (nl)
PL (1) PL1841757T3 (nl)
PT (1) PT1841757E (nl)
RS (1) RS51385B (nl)
SI (1) SI1841757T1 (nl)
SV (1) SV2008002365A (nl)
TN (1) TNSN07258A1 (nl)
TW (1) TWI312682B (nl)
UA (1) UA86283C2 (nl)
UY (1) UY29324A1 (nl)
WO (1) WO2006072828A2 (nl)
ZA (1) ZA200705427B (nl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619462A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
AR056876A1 (es) * 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
JP2009535394A (ja) * 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Pde10阻害剤としての二環式ヘテロアリール化合物
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN101611029B (zh) * 2006-12-21 2014-09-10 辉瑞产品公司 2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐
JP4792126B2 (ja) * 2007-08-01 2011-10-12 ファイザー・インク ピラゾール化合物およびRaf阻害剤としてのその使用
RU2506260C2 (ru) * 2008-06-25 2014-02-10 Энвиво Фармасьютикалз, Инк. 1,2-дизамещенные гетероциклические соединения
EP2297133B1 (en) * 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
TWI457333B (zh) 2009-02-05 2014-10-21 Takeda Pharmaceutical 嗒酮化合物
EP2400991A1 (en) 2009-02-24 2012-01-04 Janssen Pharmaceutica, N.V. Radiolabelled pde10 ligands
JP5779172B2 (ja) 2009-04-02 2015-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung オートタキシン阻害剤
DK2427454T3 (da) * 2009-05-07 2013-06-17 Envivo Pharmaceuticals Inc Heterocykliske phenoxymethylforbindelser
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
AU2010311493B2 (en) * 2009-10-30 2014-06-05 Janssen Pharmaceutica Nv Radiolabelled PDE10 ligands
AU2011221075B2 (en) 2010-02-26 2013-12-19 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as PDE10 inhibitors
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
EP2576540B1 (en) 2010-05-26 2019-09-04 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
UY33463A (es) 2010-06-24 2012-01-31 Takeda Pharmaceutical Compuestos heterocíclicos fusionados
JP5785548B2 (ja) 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
EP2675791B1 (en) 2011-02-18 2016-02-17 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US20120214842A1 (en) 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
AP2013007070A0 (en) 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders
SG193454A1 (en) 2011-03-14 2013-10-30 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production
WO2012124782A1 (ja) 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
CN103596956A (zh) 2011-06-07 2014-02-19 辉瑞大药厂 吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途
WO2013012844A1 (en) 2011-07-19 2013-01-24 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
EP2738170B1 (en) 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
RS54788B1 (sr) 2011-08-25 2016-10-31 Merck Sharp & Dohme Inhibitori pirimidina pde10
WO2013045607A1 (en) * 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
CN103159738B (zh) * 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9138494B2 (en) * 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
TW201350475A (zh) 2012-03-06 2013-12-16 Boehringer Ingelheim Int 用於組合療法之白三烯素生成之苯并二噁烷抑制劑
US8946203B2 (en) 2012-03-06 2015-02-03 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
WO2013163159A2 (en) * 2012-04-24 2013-10-31 Board Of Trustees Of Northern Illinois University Design and synthesis of novel inhibitors of isoprenoid biosynthesis
JP6256467B2 (ja) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
JP5642323B1 (ja) 2013-02-27 2014-12-17 持田製薬株式会社 新規ピラゾール誘導体
EP2970258B1 (en) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Novel inhibitor compounds of phosphodiesterase type 10a
US9464076B2 (en) 2013-03-15 2016-10-11 Daiichi Sankyo Company, Limited Benzothiophene derivative
WO2015006689A1 (en) * 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
JP2016523982A (ja) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
EP3022193B1 (en) 2013-07-15 2017-04-26 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN105793252B (zh) 2013-12-13 2018-01-30 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Pde10インヒビターならびに関連する組成物および方法
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
JP2022501335A (ja) 2018-09-28 2022-01-06 武田薬品工業株式会社 自閉症スペクトラム障害を治療または予防するためのバリポデクト(Balipodect)
TW202031250A (zh) 2018-11-06 2020-09-01 丹麥商H 朗德貝克公司 用於治療負性症狀和認知損傷之pde10a抑制劑
CN109384766B (zh) * 2018-11-19 2021-02-09 广东环境保护工程职业学院 一种喹啉类化合物及其制备方法和应用
CN109627232B (zh) * 2018-11-19 2021-02-09 广东环境保护工程职业学院 一种喹啉类化合物及其制备方法和应用
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
KR20210123321A (ko) * 2019-01-11 2021-10-13 내기스 파마슈티컬스 인코포레이티드 류코트리엔 합성 억제제
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
JP2023533724A (ja) 2020-07-02 2023-08-04 インサイト・コーポレイション Jak2 v617f阻害剤としての三環式尿素化合物
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
GB202110990D0 (en) * 2021-07-30 2021-09-15 Benevolentai Cambridge Ltd Organic compound and their uses
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
CN113956436B (zh) * 2021-11-09 2023-05-30 万华化学(宁波)有限公司 一种浅色且存储过程中色号稳定的二苯基甲烷二异氰酸酯组合物
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN116731017B (zh) * 2023-06-02 2024-10-01 海南大学 一种喹啉并哌啶类化合物及其制备方法与应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE392582B (sv) * 1970-05-21 1977-04-04 Gore & Ass Forfarande vid framstellning av ett porost material, genom expandering och streckning av en tetrafluoretenpolymer framstelld i ett pastabildande strengsprutningsforfarande
US4340480A (en) * 1978-05-15 1982-07-20 Pall Corporation Process for preparing liquophilic polyamide membrane filter media and product
US4876346A (en) 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
US4681940A (en) 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
US5627079A (en) * 1989-03-27 1997-05-06 The Research Foundation Of State University Of New York Refunctionalized oxyfluorinated surfaces
US5270193A (en) * 1989-10-27 1993-12-14 E. I. Dupont De Nemours And Company Immobilization of biomolecules on perfluorocarbon surfaces
DE69017197T2 (de) * 1990-05-18 1995-09-14 Japan Gore Tex Inc Hydrophile poröse Membrane aus Fluoropolymer.
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9202633D0 (en) * 1992-02-07 1992-03-25 Fujisawa Pharmaceutical Co Heterocyclic derivatives
DE69319391T2 (de) 1992-09-14 1998-10-29 Takeda Chemical Industries Ltd 1,2,4-Oxadiazolyl oder 1,2,4-Thiadiazolyl-Derivate als Angiotensin II Antagonisten
DE4238389A1 (de) * 1992-11-13 1994-05-19 Bayer Ag Verfahren zur Durchführung immundiagnostischer Nachweise
US5614099A (en) * 1994-12-22 1997-03-25 Nitto Denko Corporation Highly permeable composite reverse osmosis membrane, method of producing the same, and method of using the same
US6207369B1 (en) * 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US5843789A (en) * 1995-05-16 1998-12-01 Neomecs Incorporated Method of analysis of genomic biopolymer and porous materials for genomic analyses
WO1997010807A1 (en) * 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5914182A (en) * 1996-06-03 1999-06-22 Gore Hybrid Technologies, Inc. Materials and methods for the immobilization of bioactive species onto polymeric substrates
US5843958A (en) 1996-11-27 1998-12-01 Ortho Pharmaceutical Corporation Arylpyrazoles as leukotriene inhibitors
US6342292B1 (en) * 1997-12-16 2002-01-29 Asahi Kasei Kabushiki Kaisha Organic thin film and process for producing the same
US6451396B1 (en) * 1998-02-13 2002-09-17 Gore Enterprise Holdings, Inc. Flexure endurant composite elastomer compositions
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6750023B2 (en) * 1999-09-02 2004-06-15 Corning Incorporated Porous inorganic substrate for high-density arrays
US6994972B2 (en) * 1999-09-02 2006-02-07 Corning Incorporated Porous substrates for DNA arrays
US6790613B1 (en) * 1999-11-12 2004-09-14 Amersham Biosciences Ab Method of preparing an oligonucleotide array
JP2001226650A (ja) * 2000-02-16 2001-08-21 Nitto Denko Corp 放射線硬化型熱剥離性粘着シート、及びこれを用いた切断片の製造方法
US20030219816A1 (en) * 2001-07-02 2003-11-27 Keith Solomon Composite microarray slides
US6734012B2 (en) * 2000-07-05 2004-05-11 Cuno Incorporated Low fluorescence nylon/glass composites for micro-analytical diagnostic applications
US20020086307A1 (en) * 2000-07-06 2002-07-04 Murtaza Amin Combination of microporous membrane and solid support for micro-analytical diagnostic applications
TW513485B (en) * 2000-07-10 2002-12-11 Ind Tech Res Inst On-spot hydrophilic enhanced slide and preparation thereof
US6977155B2 (en) * 2000-08-10 2005-12-20 Corning Incorporated Arrays of biological membranes and methods and use thereof
EP1184349A1 (en) * 2000-09-01 2002-03-06 A.S.B.L. Facultes Universitaires Notre-Dame De La Paix Method for obtaining a surface activation of a solid support for building biochips microarrays
JP2002153272A (ja) * 2000-11-24 2002-05-28 Inst Of Physical & Chemical Res 生体分子マイクロアレイ
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
US6844028B2 (en) * 2001-06-26 2005-01-18 Accelr8 Technology Corporation Functional surface coating
US7054862B2 (en) * 2001-06-29 2006-05-30 International Business Machines Corporation Method and system for long-term update and edit control in a database system
FR2826957B1 (fr) * 2001-07-09 2005-09-30 Centre Nat Rech Scient Procede de fonctionnalisation de supports solides, supports solides fonctionnalises et leurs utilisations
WO2003014115A1 (en) 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
US20030068621A1 (en) * 2001-10-04 2003-04-10 Jonathan Briggs Method and device for producing oligonucleotide arrays
JP3884995B2 (ja) * 2002-05-29 2007-02-21 日東電工株式会社 皮膚貼着用粘着シート
US7332273B2 (en) * 2002-06-20 2008-02-19 Affymetrix, Inc. Antireflective coatings for high-resolution photolithographic synthesis of DNA arrays
EP1541149A1 (en) 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
JP2004072743A (ja) * 2002-08-05 2004-03-04 Oce Technol Bv 印刷システムにおける色の表現方法
US20030036085A1 (en) * 2002-08-19 2003-02-20 Salinaro Richard F Membranes
US20040043508A1 (en) * 2002-09-03 2004-03-04 Frutos Anthony G. Polymer-coated substrates for binding biological molecules
US20040081886A1 (en) * 2002-10-25 2004-04-29 David Zuckerbrod Separator for electrochemical devices
US20040137608A1 (en) * 2002-11-27 2004-07-15 Aaron Garzon Chemical microarrays and method for constructing same
KR100994566B1 (ko) * 2003-01-20 2010-11-15 삼성전자주식회사 고정화 영역을 갖는 포토레지스트 막을 포함하는 어레이장치 및 이를 이용한 표적 물질 검출방법
US20040152081A1 (en) * 2003-01-31 2004-08-05 Leproust Eric M. Viscosity control during polynucleotide synthesis
JP4098159B2 (ja) * 2003-05-28 2008-06-11 オリンパス株式会社 アクチュエータ駆動装置
PT1656370E (pt) 2003-06-03 2012-11-29 Rib X Pharmaceuticals Inc Compostos biaril-heterocíclicos e métodos de os produzir e de os utilizar
US20050064431A1 (en) * 2003-09-09 2005-03-24 Eastman Kodak Company Biological microarray comprising polymer particles and method of use
US20050079506A1 (en) * 2003-10-09 2005-04-14 Eastman Kodak Company Filled, biological microarray and method for use
US20050095602A1 (en) * 2003-11-04 2005-05-05 West Jason A. Microfluidic integrated microarrays for biological detection
WO2005044142A2 (en) * 2003-11-10 2005-05-19 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7323347B2 (en) * 2004-05-27 2008-01-29 Sensata Technologies, Inc. Biosensor surface structures and methods
MXPA06014236A (es) * 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
KR101159071B1 (ko) * 2005-01-14 2012-06-26 삼성전자주식회사 신규한 히드로겔 공중합체, 상기 공중합체가 코팅되어있는 기판, 상기 공중합체를 이용하여 마이크로어레이를제조하는 방법 및 그에 의하여 제조된 마이크로어레이

Also Published As

Publication number Publication date
US20060154931A1 (en) 2006-07-13
CA2592986A1 (en) 2006-07-13
HN2006000668A (es) 2010-09-17
AP2362A (en) 2012-02-08
EP1841757B1 (en) 2010-06-30
GT200600002A (es) 2006-08-01
SI1841757T1 (sl) 2010-09-30
EA200701252A1 (ru) 2007-12-28
CY1110746T1 (el) 2015-06-10
JP4302762B2 (ja) 2009-07-29
EA012211B1 (ru) 2009-08-28
DE602005022115D1 (de) 2010-08-12
NL1030863C2 (nl) 2006-12-28
EG25993A (en) 2012-11-28
CU20070156A7 (es) 2009-03-16
WO2006072828A2 (en) 2006-07-13
CA2592986C (en) 2011-02-15
US20080214607A1 (en) 2008-09-04
MY142052A (en) 2010-08-30
TWI312682B (en) 2009-08-01
TW200637555A (en) 2006-11-01
DK1841757T3 (da) 2010-09-13
NO20072918L (no) 2007-07-05
NL1030863A1 (nl) 2006-07-10
AU2005323794B2 (en) 2012-07-19
AR052863A1 (es) 2007-04-11
NO340476B1 (no) 2017-05-02
GEP20094623B (en) 2009-02-25
US7429665B2 (en) 2008-09-30
AP2007004043A0 (en) 2007-06-30
CN101098866A (zh) 2008-01-02
PE20060873A1 (es) 2006-09-04
UY29324A1 (es) 2006-08-31
CN102491969A (zh) 2012-06-13
TNSN07258A1 (fr) 2008-12-31
CR9180A (es) 2007-07-04
NZ555737A (en) 2010-01-29
UA86283C2 (uk) 2009-04-10
IL183851A (en) 2012-03-29
KR20070091005A (ko) 2007-09-06
CU23780B7 (es) 2012-02-15
PT1841757E (pt) 2010-08-31
AU2005323794A1 (en) 2006-07-13
HK1167263A1 (zh) 2012-11-23
WO2006072828A3 (en) 2006-11-09
MX2007008287A (es) 2007-09-07
ES2346674T3 (es) 2010-10-19
PL1841757T3 (pl) 2010-10-29
CN102491969B (zh) 2015-08-19
IL183851A0 (en) 2007-10-31
ATE472543T1 (de) 2010-07-15
RS51385B (en) 2011-02-28
ZA200705427B (en) 2008-09-25
BRPI0518508A2 (pt) 2008-11-25
KR100896380B1 (ko) 2009-05-08
HRP20100461T1 (hr) 2010-11-30
US7825254B2 (en) 2010-11-02
ME01142B (me) 2013-03-20
EP1841757A2 (en) 2007-10-10
SV2008002365A (es) 2008-02-08
JP2008526825A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
DOP2005000022A (es) "derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina"
MA32110B1 (fr) Derives heterocycliques bicycliques pontes ou derives heterocyclique spiro-bicycliques de pyrazolo [1,5-a] pyrimidines, procedes pour leur preparation et leurs utilisations
MA32891B1 (fr) Derives de pyridine et de pyrimidine comme inhibiteurs de phosphodiesterase 10
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30631B1 (fr) Inhibiteurs de tyrosine kinase
MA30296B1 (fr) Nouvelles amines
MA34844B1 (fr) Derives de (1,2,4) triazolo[4,3-a]quinoxaline comme inhibiteurs de phosphodiestérases
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
MA29643B1 (fr) Benzocycloheptapyridines comme inhibiteurs du recepteur tyrozine kinase met
MA38091B1 (fr) Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
WO2005115396A3 (en) Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders
WO2004087690A3 (en) Benzimidazole derivatives and their use for modulating the gaba-a receptor complex